Sanofi has appointed Belén Garijo as its new CEO, replacing Paul Hudson. Garijo’s appointment is expected to shift the company’s focus toward R&D productivity, operational efficiency, and corporate governance, which investors will closely monitor for impacts on capital allocation and strategic direction. Currently, Sanofi’s stock is evaluated by Simply Wall St as being significantly undervalued compared to analyst targets and its estimated fair value.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Sanofi Names Belén Garijo CEO As Investors Eye R&D And Valuation
Sanofi has appointed Belén Garijo as its new CEO, replacing Paul Hudson. Garijo’s appointment is expected to shift the company’s focus toward R&D productivity, operational efficiency, and corporate governance, which investors will closely monitor for impacts on capital allocation and strategic direction. Currently, Sanofi’s stock is evaluated by Simply Wall St as being significantly undervalued compared to analyst targets and its estimated fair value.